Robles BioCeutics LLC, a California-based regenerative dermatology company, announced on Friday that it has collaborated with BioCentrium.

The collaboration is aimed at advancing research into the molecular mechanisms behind Robles patent-pending Glowselle skin cream. It focuses on understanding how Glowselle mediates its regenerative impacts on aged and photodamaged skin.

Under the collaboration, BioCentrium is to utilise its proprietary cellular and molecular platforms to identify and quantify the specific pathways activated by Glowselle treatment. Robles BioCeutics is to retain all intellectual property rights stemming from this research, while BioCentrium is to receive an equity interest in the company.

Emma Lin, BioCentrium president, said: "Robles BioCeutics brings a refreshing, science-first approach to the stem cell cosmetic space, which is often dominated by marketing over substance. We've already seen exciting data from Maria Robles and her team, and we look forward to delving deeper into the science behind these results. We aim to publish our findings in a peer-reviewed journal."